Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
54.48
+0.46 (0.85%)
At close: Apr 28, 2026, 4:00 PM EDT
55.00
+0.52 (0.95%)
After-hours: Apr 28, 2026, 4:33 PM EDT
Monopar Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Monopar Therapeutics stock have an average target of 107, with a low estimate of 74 and a high estimate of 125. The average target predicts an increase of 96.40% from the current stock price of 54.48.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Monopar Therapeutics stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 13 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $100 | Strong Buy | Maintains | $100 | +83.55% | Mar 30, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $104 | Strong Buy | Reiterates | $104 | +90.90% | Feb 23, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $104 | Strong Buy | Reiterates | $104 | +90.90% | Feb 2, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $100 | Strong Buy | Maintains | $100 | +83.55% | Jan 29, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $104 | Strong Buy | Reiterates | $104 | +90.90% | Jan 14, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
22.94M
EPS This Year
-3.87
from -1.85
EPS Next Year
-4.17
from -3.87
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 41.0M | ||||||
| Avg | n/a | 22.9M | ||||||
| Low | n/a | 4.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.70 | -1.28 | ||||||
| Avg | -3.87 | -4.17 | ||||||
| Low | -7.10 | -8.69 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.